Home | Inova Search App - Admin

An Open-Label Extension Study of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD) (PERFECT OLE)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about An Open-Label Extension Study of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD) (PERFECT OLE)
An Open label, Multicenter Phase II study of the C5A-ANTIBODY IFX-1 alone or IFX-1 + PEMBROLIZUMAB in Patients with Pd-1 or Pd-L1-Resistant/Refractory Locally Advanced Or Metastatic Cutaneous Squamous Cell Carcinoma (InFla RX IFX1-P2.8)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about An Open label, Multicenter Phase II study of the C5A-ANTIBODY IFX-1 alone or IFX-1 + PEMBROLIZUMAB in Patients with Pd-1 or Pd-L1-Resistant/Refractory Locally Advanced Or Metastatic Cutaneous Squamous Cell Carcinoma (InFla RX IFX1-P2.8)
Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV melanoma (BioNTech 111-01)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV melanoma (BioNTech 111-01)
Optimizing Smoking Cessation Treatments in Smokers Living with HIV/AIDS

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about Optimizing Smoking Cessation Treatments in Smokers Living with HIV/AIDS
A Prospective Comparative Study Of Outcomes With Proton And Photon Radiation In Prostate Cancer (COMPPARE)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about A Prospective Comparative Study Of Outcomes With Proton And Photon Radiation In Prostate Cancer (COMPPARE)
The Pancreatic Early Detection Consortium (PRECEDE)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about The Pancreatic Early Detection Consortium (PRECEDE)
Patent Foramen Ovale Closure with the AMPLATZER PFO OCCLUDER in Patients with Recurrent Cryprogenic Stroke Due to Presumed Paradoxical Embolism through a Patent Foramen Ovale Who Have Failed Conventional Drug Therapy (PFO ACCESS Registry)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about Patent Foramen Ovale Closure with the AMPLATZER PFO OCCLUDER in Patients with Recurrent Cryprogenic Stroke Due to Presumed Paradoxical Embolism through a Patent Foramen Ovale Who Have Failed Conventional Drug Therapy (PFO ACCESS Registry)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Solt Tissue Sarcomas (PAZNTIS): A Phase 11/111 Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, ND# 118613)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Solt Tissue Sarcomas (PAZNTIS): A Phase 11/111 Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, ND# 118613)

Summary

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Solt Tissue Sarcomas (PAZNTIS): A Phase 11/111 Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, ND# 118613)
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors
A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)